Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355–1360 (2018).
Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98, 9237–9242 (2001).
Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. & Klinman, D. M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10, 499–511 (2011).
Klinman, D. M., Sato, T. & Shimosato, T. Use of nanoparticles to deliver immunomodulatory oligonucleotides. WIREs Nanomed. Nanobiotechnol. 8, 631–637 (2016).
Schuller, V. J. et al. Cellular immunostimulation by CpG-sequence-coated DNA origami structures. ACS Nano 5, 9696–9702 (2011).
Casaletto, J. B. & McClatchey, A. I. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat. Rev. Cancer 12, 387–400 (2012).
Shaw, A. et al. Spatial control of membrane receptor function using ligand nanocalipers. Nat. Methods 11, 841–846 (2014).
Kwon, P. S. et al. Designer DNA architecture offers precise and multivalent spatial pattern-recognition for viral sensing and inhibition. Nat. Chem. 12, 26–35 (2020).
Pulendran, B. & Ahmed, R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849–863 (2006).
Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 520, 702–705 (2015).
Leleux, J. A., Pradhan, P. & Roy, K. Biophysical attributes of CpG presentation control TLR9 signaling to differentially polarize systemic immune responses. Cell Rep. 18, 700–710 (2017).
Schmidt, N. W. et al. Liquid-crystalline ordering of antimicrobial peptide-DNA complexes controls TLR9 activation. Nat. Mater. 14, 696–700 (2015).
Lee, E. Y. et al. A review of immune amplification via ligand clustering by self-assembled liquid-crystalline DNA complexes. Adv. Colloid Interface Sci. 232, 17–24 (2016).
Comberlato, A., Koga, M. M., Nussing, S., Parish, I. A. & Bastings, M. M. C. Spatially controlled activation of Toll-like receptor 9 with DNA-based nanomaterials. Nano Lett. 22, 2506–2513 (2022).
Du, R. R. et al. Innate immune stimulation using 3D wireframe DNA origami. ACS Nano 16, 20340–20352 (2022).
Johansson, M., Denardo, D. G. & Coussens, L. M. Polarized immune responses differentially regulate cancer development. Immunol. Rev. 222, 145–154 (2008).
Yew, N. S. et al. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol. Ther. 5, 731–738 (2002).
Kumar, V. et al. DNA nanotechnology for cancer therapy. Theranostics 6, 710–725 (2016).
Udomprasert, A. & Kangsamaksin, T. DNA origami applications in cancer therapy. Cancer Sci. 108, 1535–1543 (2017).
Li, S. et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat. Biotechnol. 36, 258–264 (2018).
Liu, S. et al. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat. Mater. 20, 421–430 (2021).
Kern, N., Dong, R., Douglas, S. M., Vale, R. D. & Morrissey, M. A. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis. eLife 10, e68311 (2021).
Berger, R. M. L. et al. Nanoscale FasL organization on DNA origami to decipher apoptosis signal activation in cells. Small 17, e2101678 (2021).
Rothemund, P. W. Folding DNA to create nanoscale shapes and patterns. Nature 440, 297–302 (2006).
Douglas, S. M. et al. Self-assembly of DNA into nanoscale three-dimensional shapes. Nature 459, 414–418 (2009).
Liedl, T., Hogberg, B., Tytell, J., Ingber, D. E. & Shih, W. M. Self-assembly of three-dimensional prestressed tensegrity structures from DNA. Nat. Nanotechnol. 5, 520–524 (2010).
Shih, W. M. Exploiting weak interactions in DNA self-assembly. Science 347, 1417–1418 (2015).
Dietz, H., Douglas, S. M. & Shih, W. M. Folding DNA into twisted and curved nanoscale shapes. Science 325, 725–730 (2009).
Shen, H. et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117, 78–88 (2006).
Min, Y. et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12, 877–882 (2017).
Chesson, C. B. & Zloza, A. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine 12, 2693–2706 (2017).
Ponnuswamy, N. et al. Oligolysine-based coating protects DNA nanostructures from low-salt denaturation and nuclease degradation. Nat. Commun. 8, 15654 (2017).
Anastassacos, F. M., Zhao, Z., Zeng, Y. & Shih, W. M. Glutaraldehyde cross-linking of oligolysines coating DNA origami greatly reduces susceptibility to nuclease degradation. J. Am. Chem. Soc. 142, 3311–3315 (2020).
Lucas, C. R. et al. DNA origami nanostructures elicit dose-dependent immunogenicity and are nontoxic up to high doses in vivo. Small 18, e2108063 (2022).
Wamhoff, E. C. et al. Evaluation of nonmodified wireframe DNA origami for acute toxicity and biodistribution in mice. ACS Appl. Bio. Mater. 6, 1960–1969 (2023).
Douglas, S. M. et al. Rapid prototyping of 3D DNA-origami shapes with caDNAno. Nucleic Acids Res. 37, 5001–5006 (2009).
Njongmeta, L. M. et al. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals. Vaccine 30, 1624–1635 (2012).
Lahoud, M. H. et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl Acad. Sci. USA 109, 16270–16275 (2012).
You, C. X. et al. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: evidence for IL-12 intracrine activity in DC. Oncoimmunology 1, 847–855 (2012).
Heo, M. B., Kim, S. Y., Yun, W. S. & Lim, Y. T. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int J. Nanomed. 10, 5981–5992 (2015).
Scheuerpflug, A. et al. The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors. Cancer Immunol. Immunother. 70, 1343–1350 (2020).
Keestra, A. M., de Zoete, M. R., Bouwman, L. I. & van Putten, J. P. Chicken TLR21 is an innate CpG DNA receptor distinct from mammalian TLR9. J. Immunol. 185, 460–467 (2010).
Oldenburg, M. et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 337, 1111–1115 (2012).
Spies, B. et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171, 5908–5912 (2003).
Yu, D. et al. ‘Immunomers’–novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 30, 4460–4469 (2002).
Minari, J., Mochizuki, S. & Sakurai, K. Enhanced cytokine secretion owing to multiple CpG side chains of DNA duplex. Oligonucleotides 18, 337–344 (2008).
Smith, L. K. et al. Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity 48, 299–312 e295 (2018).
Li, A. W. et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat. Mater. 17, 528–534 (2018).
Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).
Toubi, E. & Shoenfeld, Y. Protective autoimmunity in cancer (review). Oncol. Rep. 17, 245–251 (2007).
Ke, Y., Voigt, N. V., Gothelf, K. V. & Shih, W. M. Multilayer DNA origami packed on hexagonal and hybrid lattices. J. Am. Chem. Soc. 134, 1770–1774 (2012).
Douglas, S. M., Chou, J. J. & Shih, W. M. DNA-nanotube-induced alignment of membrane proteins for NMR structure determination. Proc. Natl Acad. Sci. USA 104, 6644–6648 (2007).
Hahn, J., Wickham, S. F., Shih, W. M. & Perrault, S. D. Addressing the instability of DNA nanostructures in tissue culture. ACS Nano 8, 8765–8775 (2014).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41565-024-01615-3
